

Post-Acute-COVID-19-Illness Pulmonary Sequelae

Attapon Cheepsattayakorn^{1,3*}, Ruangrong Cheepsattayakorn² and Porntep Siriwanarangsun³

¹10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

²Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

³Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding author

Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand

Submitted: 14 Jun 2021; Accepted: 19 Jun 2021; Published: 30 Jun 2021

Citation: Attapon Cheepsattayakorn, Ruangrong Cheepsattayakorn and Porntep Siriwanarangsun (2021) Post-Acute-COVID-19-Illness Pulmonary Sequelae. *Adv Bioeng Biomed Sci Res* 4(2): 08-09.

Pulmonary function abnormalities in post-acute-COVID-19-illness survivors could be due to a decrease in both diffusing capacity of the lung for carbon dioxide (DLCO) and transfer coefficient of the lung for carbon monoxide (KCO) [1]. Alveolar-capillary damage, microvascular pathological lesions, or anemia can contribute to reduction of the KCO [1]. Post-acute-COVID-19-illness pulmonary fibrosis and post-acute-MERS-associated pulmonary fibrosis were highly associated with old aging ranging from 60- to 70-years age group (13 out of 30 (43.3 %)), demonstrated by Wong et al and Das et al [2, 3]. Post-acute-COVID-19-illness pulmonary fibrosis was 1.3 times more predominant in males, compared to females, possibly explained by the effect of androgen that promotes the transcription of transmembrane protease serine 2 gene, and was much higher incidence in cigarette smoker (18 of 30 patients (60 %)), compared to non-smoking patients [4, 5]. This gene impairs host's antibody response and facilitates the fusion of the virus-host cells [4]. Dyspnea, the most common persistent symptom of the pulmonary sequelae ranged from 42 % to 66 % prevalence at 60-100 days of following-up [6-9], supported by the result of lower median 6-minutes walking distance comparing to the normal reference values in one-fourth of the patients at 6 months in the post-acute-COVID-19-illness Chinese study that was similar to the prevalence in SARS and MERS survivors [10, 11].

Lungs of the post-acute-COVID-19-illness survivors demonstrated endothelial- cell-dysfunction vasculitis [12]. Detected incident-clinical sequelae that are commonly identified in other serious viral infections, such as kidney injury, stroke, and hypertension was nearly twice, compared to a normal-year-incidence in general population, suggesting more urgently needed planning for healthcare resources for management of the COVID-19 survivors' health complications [13]. Post-acute-COVID-19-illness pulmonary aspergillosis that frequently are associated with acute respiratory distress syndrome (ARDS) could be due to host factors, such as poorly controlled diabetes, anti-interleukin 6 (tocilizumab) treatment in hospitalized post-acute-COVID-19-illness patients, and long-term use of corticosteroids in severe COVID-19-asso-

ciated pneumonia, in addition to damage to the respiratory epithelium directly caused by SARS-CoV-2 (COVID-19) resulting in mucociliary dysfunction and fungal invasion of the respiratory epithelium. Serum galactomannan levels, chest roentgenographic and chest computerized tomographic imaging, and fungal isolation in the bronchoalveolar lavage or bronchial washing or tracheal aspirates are the diagnostics [14]. The proposed first-line treatment for these pulmonary sequelae is isavuconazole or voriconazole [14]. Additionally, pulmonary and rhino-orbital-cerebral mucormycosis are the other two mold-related manifestations found in the post-acute-COVID-19 survivors. Biopsy with fungal isolation is the gold standard of diagnosis, whereas the initial treatment includes surgical debridement with intravenous amphotericin-B switching by oral posaconazole for avoiding nephrotoxicity [15]. Blood-stream-candida infection (invasive candidiasis), a late complication of COVID-19-related pneumonia in 15 post-acute-COVID-19-illness patients in New Delhi, India was also reported [16].

In conclusion, prediction of pulmonary fibrosis in potential-high-risk-post-acute-COVID-19-illness patients could assist in decreasing the morbidity and mortality by introduction of early medical therapeutics, such as anti-fibrotic agents.

References

1. Chen R, Gao Y, Chen M, Jian W, Lei C, et al. (2020) Impaired pulmonary function in discharged patients with COVID-19 : more work ahead. *Eur Respir J* 56: 2002194.
2. Wong K, Antonio GA, Hui DS, Catherine Ho, Po-nin Chan, et al. (2002) Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinico-radiologic correlation during the convalescent period. *J Comput Assisted Tomogr* 28: 790-795.
3. Sansone A, Mollaioli D, Ciocca G, Limoncin E, Vena W, et al. (2021) Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. *J Endocrinol Invest* 44: 223-231.

-
4. Lee EY, Singh R (2017) Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian J Radiol Imag* 27: 342-349.
 5. Vardavas CI, Nikitara K (2020) COVID-19 and smoking: a systematic review of the evidence. *Tob Induc Dis* 18: 20.
 6. Carfi A, Bernabei R, Landi F (2020) Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. *JAMA* 324: 603-605.
 7. Garrigues E, Janvier P, Kherabi Y, Audrey Le Bot, Antoine Hamon, et al. (2020) Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect* 81: 4-6.
 8. Chopra V, Flanders SA, O'Malley M (2020) Sixty-day outcomes among patients hospitalized with COVID-19. *Ann Intern Med* 2020.
 9. Halpin SJ, Claire McIvor, Gemma Whyatt, Anastasia Adams, Olivia Harvey, et al. (2021) Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection : a cross-sectional evaluation. *J Med Virol* 93: 1013-1022.
 10. Huang C, Lixue Huang, Yeming Wang, Xia Li, Lili Ren, et al. (2021) 6-month consequences of COVID-19 in patients discharged from hospital : a cohort study. *Lancet* 397: 220-232.
 11. Ahmed H, Kajal Patel, Darren C Greenwood, Stephen Halpin, Penny Lewthwaite, et al. (2020) Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalization or ICU admission : a systematic review and meta-analysis. *J Rehabil Med* 52: jrm00063.
 12. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, et al. (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. *N Engl J Med* 383: 120-128.
 13. Davis HE, Assaf GS, McCorkell L, Ryan J Low, Yochai Re'em, et al. (2021) Characterizing long COVID in an international cohort : 7 months of symptoms and their impact. *MedRxiv* 2021.
 14. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, et al. (2020) Defining and managing COVID-19-associated pulmonary aspergillosis : the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infect Dis* 21: 149-162.
 15. Kumar UV (2021) Post-COVID-19 sequelae. *Indian Journal of Respiratory Care* 10: 60-66.
 16. Chowdhary A, Tarai B, Singh A, Sharma A (2020) Multi-drug-resistant candida auris infections in critically ill coronavirus disease patients, India, April-July 2020. *Emerg Infect Dis* 26: 2694-2696.

Copyright: ©2021 Attapon Cheepsattayakorn, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.